Edwards Lifesciences Corp (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $112.15, for a total transaction of $594,395.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Donald E. Bobo, Jr. also recently made the following trade(s):

  • On Friday, August 4th, Donald E. Bobo, Jr. sold 25,000 shares of Edwards Lifesciences Corp stock. The stock was sold at an average price of $116.00, for a total transaction of $2,900,000.00.
  • On Friday, July 28th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences Corp stock. The stock was sold at an average price of $114.68, for a total transaction of $607,804.00.
  • On Thursday, June 29th, Donald E. Bobo, Jr. sold 5,600 shares of Edwards Lifesciences Corp stock. The stock was sold at an average price of $117.15, for a total transaction of $656,040.00.

Shares of Edwards Lifesciences Corp (NYSE EW) traded up 0.77% during midday trading on Wednesday, hitting $112.69. 929,201 shares of the company’s stock were exchanged. Edwards Lifesciences Corp has a 1-year low of $81.12 and a 1-year high of $121.75. The stock has a market cap of $23.80 billion, a PE ratio of 34.18 and a beta of 0.63. The stock’s 50 day moving average is $115.76 and its 200-day moving average is $106.74.

Edwards Lifesciences Corp (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corp had a return on equity of 26.27% and a net margin of 22.11%. The company had revenue of $842 million during the quarter, compared to analysts’ expectations of $839.16 million. During the same period in the prior year, the business earned $0.76 earnings per share. Edwards Lifesciences Corp’s revenue for the quarter was up 10.9% compared to the same quarter last year. Analysts predict that Edwards Lifesciences Corp will post $3.78 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/30/donald-e-bobo-jr-sells-5300-shares-of-edwards-lifesciences-corp-ew-stock.html.

Several large investors have recently bought and sold shares of EW. YorkBridge Wealth Partners LLC acquired a new stake in Edwards Lifesciences Corp during the first quarter valued at $110,000. ETF Managers Group LLC acquired a new stake in Edwards Lifesciences Corp during the second quarter valued at $112,000. NEXT Financial Group Inc boosted its stake in Edwards Lifesciences Corp by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock valued at $115,000 after buying an additional 500 shares in the last quarter. Shine Investment Advisory Services Inc. acquired a new stake in Edwards Lifesciences Corp during the second quarter valued at $126,000. Finally, Cornerstone Advisors Inc. boosted its stake in Edwards Lifesciences Corp by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after buying an additional 219 shares in the last quarter. 82.36% of the stock is owned by institutional investors.

Several research firms have weighed in on EW. BidaskClub upgraded shares of Edwards Lifesciences Corp from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 22nd. Canaccord Genuity reiterated a “buy” rating and issued a $150.00 target price on shares of Edwards Lifesciences Corp in a report on Wednesday, June 28th. Zacks Investment Research lowered shares of Edwards Lifesciences Corp from a “buy” rating to a “hold” rating in a report on Thursday, June 8th. Jefferies Group LLC reiterated a “buy” rating and issued a $115.00 target price on shares of Edwards Lifesciences Corp in a report on Friday, June 30th. Finally, SunTrust Banks, Inc. boosted their target price on shares of Edwards Lifesciences Corp to $14.00 and gave the company a “buy” rating in a report on Monday, July 17th. Six equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $120.18.

Edwards Lifesciences Corp Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corp (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with MarketBeat.com's FREE daily email newsletter.